Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimetabolites.

C J Allegra, J L Grem, G C Yeh

    Cancer Chemotherapy and Biological Response Modifiers
    |January 1, 1988
    PubMed
    Summary
    This summary is machine-generated.

    Understanding drug mechanisms like methotrexate (MTX) and 5-fluorouracil (5-FU) is key for new cancer therapies and overcoming drug resistance. Pharmacokinetics predict relapse in acute leukemia, guiding treatment optimization.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Pulsed radiofrequency inhibited activation of spinal mitogen-activated protein kinases and ameliorated early neuropathic pain in rats.

    European journal of pain (London, England)·2014
    Same author

    Altered bone development in a mouse model of peripheral sensory nerve inactivation.

    Journal of musculoskeletal & neuronal interactions·2014
    Same author

    Trends in the epidemiology, diagnosed age and mortality rate of haemophiliacs in Taiwan: a population-based study, 1997-2009.

    Haemophilia : the official journal of the World Federation of Hemophilia·2014
    Same author

    Cytidine and deoxycytidylate deaminase inhibition by uridine analogs.

    Biochemical pharmacology·2010
    Same author

    Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid.

    British journal of pharmacology·2007
    Same author

    DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.

    British journal of cancer·2003
    Same journal

    Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    DNA vaccines for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Chemotherapy, cytokines, and biochemotherapy for melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    Same journal

    Current status of interferon-alpha in the treatment of melanoma.

    Cancer chemotherapy and biological response modifiers·2005
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Biochemistry

    Background:

    • Elucidation of mechanisms of action for methotrexate (MTX) and 5-fluorouracil (5-FU) is crucial for advancing cancer chemotherapy.
    • Understanding drug transport and optimal levels of MTX and cytarabine (ara-C) can aid in developing new analogs and treatment strategies.
    • Pharmacokinetic parameters, especially for MTX, 6-mercaptopurine (6-MP), and ara-C, are significant predictors of relapse in pediatric acute leukemia.

    Purpose of the Study:

    • To further elucidate the mechanisms of action of MTX and 5-FU.
    • To explore predictors of treatment response and relapse in acute leukemia.
    • To investigate novel strategies for overcoming antimetabolite resistance in cancer treatment.

    Main Methods:

    • Studies on drug transport and intracellular drug levels.

    Related Experiment Videos

  • Correlation of pharmacokinetic parameters with relapse and remission duration.
  • Development of assay systems, including NMR spectroscopy for in vivo 5-FU pharmacokinetics.
  • Investigation of mechanisms of MTX resistance, including target enzyme amplification and altered membrane transport.
  • Exploration of novel approaches to overcome antimetabolite resistance.

    • Main Results:

    • Pharmacokinetic parameters predict relapse in children with acute leukemia, with ara-C half-life correlating with remission duration in AML.
    • High-frequency MTX resistance can emerge rapidly, potentially via target enzyme amplification or altered membrane transport.
    • MTX resistance is a frequent event in multidrug-resistant cells, suggesting a broader resistance phenomenon.
    • Novel strategies involving biochemical modulators and gene transfection are being explored to overcome resistance.

    Conclusions:

    • Further understanding of MTX and 5-FU mechanisms is vital for designing effective drug combinations and novel analogs.
    • Optimizing drug transport and levels can improve therapeutic outcomes.
    • Identifying resistance mechanisms is critical for developing strategies to enhance treatment efficacy in human malignancies.
    • These studies provide a foundation for developing more effective cancer treatment strategies.